Recent studies suggest that erectile dysfunction (ED) may be an early marker of endothelial dysfunction and coronary artery disease (CAD). Conversely, patients with CAD commonly have ED. The phosphodiesterase 5 (PDE5) inhibitors are very effective for the treatment of ED in patients with CAD. Numerous studies show that this class of drugs is in general safe in patients with stable CAD and these agents do not exacerbate ischemia in men with CAD undergoing exercise stress testing. Analysis of placebo-controlled trials did not show an increase in cardiovascular events among men receiving PDE5 inhibitors, and post-marketing surveillance studies with sildenafil did not observe an increase in cardiovascular events compared to expected age-matched rates. Organic nitrates remain a contraindication for PDE5 inhibitors and alpha blockers have precautions/contraindications depending upon specific drugs. The Princeton Consensus Guidelines (soon to be updated) suggest a logical approach to the patient with CAD seeking therapy for sexual dysfunction.
Erectile dysfunction (ED) as an early warning of vascular disease
It is now well documented that many of the risk factors for coronary artery disease (CAD) (hypertension, smoking, dyslipidemia, diabetes, lack of physical exercise) are risk factors for erectile dysfunction (ED). 1, 2 The reason for this is that both of these conditions-CAD and ED-may have in common endothelial dysfunction. The shared risk factors contribute to endothelial dysfunction and impede the ability of the arteries to dilate properly in response to stimuli. If arteries cannot properly dilate, then a normal erection will not occur.
Several studies have suggested that ED may be an early marker of endothelial dysfunction and CAD in some men. Blumentals et al 3 found that men with ED had a two-fold increase in the risk for acute myocardial infarction (MI) after correcting for age, smoking, obesity, and use of angiotensin-converting enzyme inhibitors, beta blockers, and statins. Kaiser et al 4 described systemic vascular structure and function in 30 men with ED and 27 age-matched controls. These investigators performed urologic evaluation and penile Doppler studies on the subjects and administered ED questionnaires. Helical computed tomography was obtained to determine a noninvasive coronary artery calcium assessment and ultrasound was used to assess brachial and carotid artery properties. Patients with ED had evidence of penile vascular disease by Doppler coupled with a reduced International Index of Erectile Function (IIEF) score. Brachial artery flow-mediated vasodilation was reduced in the ED patients (1.3%) vs the normal group (2.4%; P ¼ 0.014). In addition, vasodilation to nitroglycerin was reduced in ED patients (13.0%) compared to normals (17.8%; Po0.05). Coronary calcium scores, carotid and brachial artery diameters, and intimamedial thickness were similar between groups. The authors concluded that patients with ED but no manifest clinical heart or vascular disease have a vascular defect in both endothelium-dependent and -independent vasodilation that occurs prior to the development of frank functional or structural vascular disease. 4 O'Kane and Jackson 5 reported the case of a patient who developed ED 2 months prior to an acute MI and a patient with ED, which prompted an evaluation leading to the discovery of multivessel CAD by angiography.
Pritzker et al 6 reviewed stress test results, risk profiles, and, where available, coronary angiograms in 50 men with ED, but without overt cardiovascular disease. In these men between the ages of 40 and 60, multiple risk factors for CAD were present in 80%. Exercise stress testing was electrocardiographically positive for ischemia in 28 of 50 patients. In 20 patients who underwent coronary angiography, the left main CAD or severe three-vessel disease was present in six, two-vessel disease in seven, and single-vessel disease in seven patients. Pritzker 6 coined the term 'The penile stress test', suggesting that ED may be an early warning of cardiovascular disease.
Taken together, the above studies suggest that when a man presents with ED, he should be evaluated for the cardiovascular risk factors of hypertension, smoking, dyslipidemia, diabetes, and lack of physical exercise. In addition, these studies suggest that ED may be an early warning that the man is at risk of developing vascular abnormalities with either endothelial dysfunction and/or a defect in endothelium-independent vasodilation or possibly frank atherosclerotic CAD. As Montorsi et al 7 recently wrote, ED may be the 'Tip of the Iceberg' of a systemic vascular disorder.
The presence of ED in men with known CAD ED has been reported in patients with known CAD such as MI. 8 How common is ED in men with stable chronic CAD? In order to address this question, we 9 administered the Sexual Health Inventory for Men (SHIM), a validated five-question questionnaire based on the IIEF questionnaire, to 76 male patients (mean age 64 y (40-82)) with chronic stable CAD during routine outpatient cardiology visits. Most of these men had not previously discussed ED with their cardiologist. Their medications included beta blockers (47%), statins (92%), and diuretics (28%). Among the 76 men, 53 (70%) had a SHIM score ofr 21, which is indicative of ED. The questionnaire results demonstrated that 57 (75%) of the men had ED or a recent history of ED. Sildenafil treatment resulted in SHIM scores of 23-25, which indicates near normalization of ED. These efficacy results mirror the success rates previously demonstrated in larger studies of patients with CAD. Clearly, ED is extremely common in the population of men with chronic CAD who are routinely seen in cardiologists' offices, affecting 75% of men; yet most cardiologists do not ask about ED. Successful treatment of this population is readily possible utilizing sildenafil.
Efficacy of phosphodiestrase type5 (PDE5) inhibitors in CAD patients
In 1998, a new class of drugs was heralded by sildenafil citrate, an orally administered, potent and selective PDE5 inhibitor. Initially a candidate antianginal agent and two newer PDE5 inhibitorsvardenafil and tadalafil-have become the global cornerstone of medical therapy for ED. PDE5 is found in the trabecular smooth muscle of the corpora cavernosa as well as in the smooth muscle of arteries and veins. It is not found in cardiac myocytes or the cells of the conducting system. The mechanism of action of sildenafil and other PDE5 inhibitors is to enhance the endogenous signal transduction process. Initially, upon sexual simulation, efferent neurotransmission in the trabecular smooth muscle of the corpora cavernosa releases nitric oxide, a fleeting neurotransmitter that diffuses into the smooth muscle cells and activates guanylate cyclase, which in turn increases the production of cyclic guanosine monophosphate (cGMP). Through the intracellular sequestration and extracellular translocation of calcium, cGMP produces smooth muscle relaxation with subsequent increases in arterial inflow and veno-occlusion. Thus, cGMP mediates the events of sexual stimulation. Sildenafil amplifies these events by decreasing the degradation of cGMP through the inhibition of PDE5, the enzyme that breaks down cGMP.
Efficacy of sildenafil in coronary patients
In an early study by Conti et al, 10 sildenafil was found to be highly effective in men with ED who had ischemic heart disease. In all, 70% of men reported improved erections with sildenafil. DeBusk et al 11 have recently re-examined the efficacy and safety of sildenafil in men with ED and chronic stable CAD. In a double-blind, placebo-controlled study of men with ED and stable CAD, patients were randomized to receive sildenafil vs placebo for 12 weeks. Primary outcomes were questions 3 and 4 of the IIEF. By the 12th week of the study, sildenafiltreated patients (n ¼ 70) had significant improvements on questions 3 (frequency of penetration) and 4 (frequency of maintained erections after penetration) vs the placebo-treated patients (n ¼ 72; Po0.01). In addition, 64% of sildenafil-treated patients reported improved erection vs 21% of placebo patients, and 65% of sildenafil-treated patients reported improved intercourse vs 19% of placebo patients. There were no serious drug-related cardiac events. The authors concluded that sildenafil is effective and well-tolerated for ED in men with CAD.
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Olsson et al 12 reported a randomized, doubleblind, placebo-controlled, parallel group, flexibledose study of sildenafil in 224 men with at least one cardiovascular disease, including hypertension (80%) and ischemic heart disease (20%), who had ED. These men were receiving treatment with beta blockers and/or angiotensin-converting enzyme inhibitors and/or calcium blockers, but not organic nitrates. Following a 4-week run-in phase, patients received either sildenafil 50 mg or placebo 1 h prior to planned sexual activity. Mean end-of-treatment scores for question 3 of the IIEF (ability to achieve an erection) was greater in the sildenafil group (3.7) than the placebo group (2.2). Mean end-of-treatment scores for question 4 of the IIEF (ability to maintain an erection) was also greater in the sildenafil group (3.3) than the placebo group (1.9; P ¼ 0.0001). In all, 71% of patients receiving sildenafil reported improved erections on the global efficacy question, vs only 24% of placebo patients (P ¼ 0.0001). No treatment-related adverse cardiovascular events were noted in the sildenafil group.
Thus, studies to date suggest that a high percentage of men with CAD plus ED respond favorably to the PDE5 inhibitor sildenafil. Data specific to CAD patients have yet to be reported for the other two PDE5 inhibitors in the US market (tadalafil and vardenafil).
Safety of PDE5 inhibitors in the coronary artery patient

Exercise testing
There are numerous studies that have investigated the issue of safety of PDE5 inhibitors in the coronary patient. Several have focused on the administration of these agents during exercise stress tests to determine whether they exacerbate ischemia. Arruda-Olson et al 13 published a randomized, doubleblind, placebo-controlled, crossover trial involving 105 men 440 y of age with ED and known or highly suspected CAD. CAD was defined as having any of the following:
Z50% diameter stenosis of a major epicardial artery or one of its major branches; a history of MI; a prior positive stress-imaging result; a prior coronary artery bypass surgery or angioplasty; a high (470%) pretest probability of CAD according to the presence of typical angina pectoris.
Major exclusion criteria were asthma, severe aortic stenosis, hypertrophic obstructive cardiomyopathy, unstable angina, recent MI (o1 month), congestive heart failure, or a systolic blood pressure (BP) o90 mmHg. Long-acting nitrates were discontinued at least 72 h before testing. The sildenafil dose was 50 mg unless a different dose was recommended by the patient's physician. All patients underwent two symptom-limited exercise echocardiograms separated by 1-3 days; all cardioactive medications were continued. Subjects were randomized in a double-blind crossover design to 50 or 100 mg sildenafil or placebo, to be taken 1 h before the exercise test. Baseline echocardiographic images were obtained, and the test was repeated 1 h after drug administration. Exercise echocardiograms were performed on a supine bicycle attached to a table tilted 30-451 to the left. Subjects began exercising at 25 W, with a 25-W increase at 2-min intervals. Echocardiographic imaging was performed continuously during each stage of the exercise protocol. The criteria for test termination were: development of symptoms including fatigue; a decrease in systolic BP 410 mmHg; ventricular dilation or global reduction of systolic function; and significant arrhythmia.
Of 110 men randomized, 105 (sildenafil given first, n ¼ 53; placebo given first, n ¼ 52) were included in the analysis. The mean age was 66 y; 89% of men had known CAD, and 28% had typical angina pectoris. A total of 92% of men received the 50-mg dose of sildenafil, and 7% received the 100-mg dose. The baseline ECG result was abnormal in 56% of patients, and resting wall motion abnormalities on echocardiography were present in 57% of patients. The baseline mean resting ejection fraction was 56%. Resting heart rate and diastolic BP did not change significantly after sildenafil administration; systolic BP showed a mean decrease of 7 mmHg (Po0.001) with sildenafil and 3 mmHg with placebo (P ¼ 0.08). Resting wall motion (wall motion score index (WMSI)) did not change significantly after sildenafil administration. Exercise-induced wall motion abnormalities developed in a similar number of men with sildenafil (n ¼ 84) or placebo use (n ¼ 86), and the WMSI at peak exercise was similar after sildenafil or placebo use (1.4 in both groups). Symptoms of dyspnea or angina developed in 69 men from the sildenafil group and 70 men from the placebo group. There were no deaths, acute MIs, or episodes of ventricular fibrillation associated with exercise studies.
The conclusion of the study was that in this prospective, randomized, crossover study in men with ED and known or probable CAD, sildenafil administered 1 h before exercise testing was well tolerated and did not change the onset, extent, or severity of ischemia.
In a second study, Fox et al 14 examined the effect of sildenafil on exercise-induced angina in men at the time of a treadmill test. This was a double-blind, parallel-group, placebo-controlled, multicenter study in men with ED and chronic stable angina, assessing the effect of sildenafil on the time to onset Erectile dysfunction in coronary heart disease R Kloner and H Padma-Nathan of limiting angina during incremental exercise. Patients with reproducible exercise-induced angina received a 100-mg dose of sildenafil or placebo 1 h prior to treadmill exercise. The primary end point was time to limiting angina. Secondary end points included time to onset of angina, time to 1 mm ST-segment depression, total exercise time, BP, heart rate, and rate pressure product (RPP).
In the evaluable patients, sildenafil (n ¼ 56) significantly increased both the time to limiting angina and time to onset of angina, as well as exercise duration, compared with placebo (n ¼ 52). Adjusted treatment differences (sildenafil minus placebo) were 19.979.6 s (P ¼ 0.04), 31.7710.7 s (P ¼ 0.0039), and 19.579.8 s (P ¼ 0.05), respectively. Systolic blood was lower prior to and during exercise in the sildenafil group, with little difference in heart rate between groups. Rate-pressure product was lower post drug in the sildenafil group at rest, during exercise, and throughout the recovery period. There were no serious treatment-related adverse events.
The conclusion of this study was that sildenafil did not adversely affect any exercise parameter in men with severe CAD and ED; the time to limiting angina was improved by 9.8% with sildenafil.
In another study, Patrizi et al 15 found that sildenafil did not worsen exercise capacity or worsen exercise-induced ischemia in patients whose angina was successfully managed on betablockers. Thadani et al 16 studied the effects of vardenafil in men with chronic angina undergoing an exercise stress test. In this double-blind, crossover, single-dose, multicenter study, 41 men with reproducible, stable, exertional, exercise-induced angina due to ischemia received vardenafil 10 mg or placebo, followed by exercise treadmill testing (5-10 METS, Bruce protocol) 1 h post-dose. All nitrates were discontinued at least 24 h prior to study. End points included symptom-related ETT time, time to first awareness of angina, and time to ischemia threshold. Vardenafil relative to placebo did not alter ETT time or time to first awareness of angina. It did increase the time to ischemic threshold (from 334 to 381 s; P ¼ 0.0004). Vardenafil 10 mg did not impair the ability of patients with stable CAD to exercise at levels equivalent to those attained at sexual intercourse.
A preliminary report by Patterson et al 17 described the effect of the long-acting PDE5 inhibitor tadalafil on exercise stress testing. In all, 23 patients with stable CAD underwent a screening exercise test (Z5 METS). They then received either tadalafil 10 mg or placebo 2-2.5 h prior to exercise testing. There was no difference in total exercise time/time to ischemia between groups (B13 min). Changes in heart rate and BP were similar between treatment groups.
Thus, to date PDE5 inhibitors do not appear to exacerbate ischemia or worsen exercise tolerance in patients with known CAD who achieve levels of exercise comparable or greater than that achieved during sexual intercourse.
The effect of sildenafil on human coronary arteries
In a landmark lead article in the New England Journal of Medicine, Hermann et al 18 examined the effects of oral sildenafil (100 mg) in men with severe CAD at the time of cardiac catheterization and planned subsequent angioplasty. Study subjects were 14 men with stable angina and at least one severely stenosed (470% of the vessel diameter) coronary artery, who had been referred for percutaneous revascularization. Nitrates were discontinued at least 24 h before the start of the study. Hemodynamic measurements included arterial BP, pulmonary artery pressure, pulmonary capillary wedge pressure, and right atrial pressure. Heart rate and cardiac output were determined by thermodilution. Systemic and pulmonary vascular resistance and their indexes were calculated. Angiography was performed. Average peak velocity and coronary flow reserve at baseline were measured before and after intracoronary administration of adenosine. After baseline measurements were completed, 100 mg sildenafil was administered; all measurement were repeated 45 min later. Percutaneous coronary revascularization was performed at the end of the study. For the 14 patients (mean7s.d. age, 61711 y), the mean7s.d. degree of stenosis of at least one coronary artery was 7877%. Among these men, 57% were smokers, 57% had hypertension, 43% had diabetes, and 36% had a previous MI.
Small decreases (o10%) were observed in arterial systolic, diastolic, and mean BP and in systolic and mean pulmonary pressures. There were no significant changes in pulmonary capillary wedge pressure, right atrial pressure, heart rate, cardiac output, cardiac index, or calculated systemic and pulmonary vascular resistances and their indexes. The double product (heart rate Â systolic BP) also decreased. Sildenafil produced no significant changes in average peak velocity of coronary flow at baseline, coronary artery diameter, coronary blood flow, or coronary vascular resistance. However, the hyperemic average peak velocity and coronary flow reserve increased 13% after administration of sildenafil; the effect was consistently observed in both stenosed and reference arteries. In the 11 men in whom measurements were made in both a stenosed and reference artery, relative coronary reserve (ratio of coronary flow reserve in diseased to reference vessels) was unchanged by sildenafil (0.5770.14 at baseline vs 0.5770.15 after sildenafil, P ¼ 0.90).
The authors concluded that no adverse cardiovascular effects of oral sildenafil were detected in men Erectile dysfunction in coronary heart disease R Kloner and H Padma-Nathan with severe CAD. These findings support the American College of Cardiology/American Heart Association consensus position that sildenafil is safe for patients with stable CAD who are not taking nitrates. 19 The effects of tadalafil and vardenafil on central hemodynamics (including cardiac output) and coronary artery function remain to be determined.
The effect of sildenafil on resting coronary vascular tone, and endothelium-dependent and -independent function and platelet activation, was measured in 24 men in a study by Halcox et al. 20 In addition, 24 other men with CAD and ischemia during exercise, and 12 control subjects, received either 100 mg sildenafil, 10 mg isosorbide dinitrate (ISDN) or placebo during exercise on three separate days in a randomized, double-blind manner. Flowmediated dilation of the brachial artery was measured, and coronary patients underwent exercise treadmill testing (ETT).
Sildenafil vasodilated epicardial coronary arteries ( þ 6.971.3%, Po0.0001). Coronary epicardial and microvascular responses with acetylcholine and cold pressor testing improved with a greater enhancement in patients with CAD and endothelial dysfunction. Responses to verapamil were unchanged by sildenafil. Both resting and adenosine diphosphate-stimulated platelet IIb/IIIa receptor activation was inhibited by sildenafil (Po0.05). Brachial arteries dilated in response to sildenafil in controls. Peak flow-mediated dilation was similar, but the duration of hyperemia was prolonged after sildenafil administration (Po0.001). Compared with placebo, isosorbide dinitrate improved myocardial ischemia during ETT (Po0.05), whereas the effect of sildenafil was intermediate between the two. Sildenafil dilates epicardial coronary arteries, improves endothelial dysfunction, and inhibits platelet activation in patients with CAD. It has an intermediate effect on myocardial ischemia compared with isosorbide dinitrate and placebo.
Do PDE5 inhibitors precipitate acute cardiac events?
Shortly after release of the first PDE5 inhibitor, sildenafil, there were anecdotal reports of acute cardiac events (including cardiac death and MI) in men who were receiving this agent. The questions that arose included: (1) was the PDE5 inhibitor triggering these events, or (2) were these events due to the increased oxygen demand of sexual activity, or (3) would these events have occurred unrelated to the medicine, given the ages of the patients and their underlying risk factors? In order to answer these questions several analyses have been performed. In open label studies, the rate of MI or death in patients on sildenafil was even lower at 0.56 (95% CI ¼ 0.44-0.72) per 100 patient-years followup. The authors concluded that rates of MI and cardiovascular death were low and comparable between sildenafil and placebo treatments. These results confirmed earlier reports by Morales et al, 22 Padma-Nathan et al, 23 Steers et al, 24 Christiansen et al, 25 as well as a study by Olsson, which was specifically conducted in patients with known cardiovascular disease. 12 Several similar analyses have recently been reported for tadalafil. In the first report by Emmick et al, 26 the incidence of MI across tadalafil doubleblind studies in 42500 patients receiving tadalafil was 0.28 per 100 patient-years vs in 41200 placebo patients in whom the incidence was 1.1 per 100 patient-years. The incidence in open-label tadalafil studies was 0.43 per 100 patient-years. Cardiac mortality in tadalafil-treated patients was less than 2.0 per 1000 patient-years, which is similar to cardiac mortality rates in an age-standardized British Male population (2.6/1000 patient-years). 27 An update of this analysis was reported by Kloner et al, 28 including data on 1437 placebo patients, 3666 tadalafil double-blind treatment, and 1707 tadalafil open-label long-term studies. The rate of MI per 100 patient-years was 0.60 in placebo patients, 0.25 in tadalafil double-blind patients, and 0.50 in tadalafil open-label studies. For an age-standardized reference male population, the rate of MI per 100 patient-years is 0.60. A reassessment of cardiac mortality showed that it was no higher than expected in this population of men.
A very recent update by Jackson et al 29 showed that the rate of MI across controlled and open-label studies was 0.33 per 100 patient-years among 10 460 patients treated with tadalafil vs 0.41 per 100 patient-years among 2118 patients receiving placebo. A small study by McMahon 30 described 112 men with moderate to severe ED treated with daily 10 or 20 mg of tadalafil for 12 weeks. Daily dosed tadalafil improved efficacy compared to pretreatment and ondemand tadalafil. Two patients developed nonfatal MIs; both had multiple risk factors for vascular disease. The authors did not consider the infarcts 'treatment related'; however, this was a greater rate of MI than previously reported. Although this was a rather small study, future studies will need to assess the issue of daily rather than on-demand therapy, and cardiovascular safety and post marketing surveillance studies with the newer PDE5 inhibitors will be important.
A preliminary report regarding five controlled clinical trials with vardenafil also did not demonErectile dysfunction in coronary heart disease R Kloner and H Padma-Nathan strate an increase in adverse cardiovascular events with this agent compared to placebo. 31 
Post-marketing surveillance studies
Post-marketing surveillance studies are important for a number of reasons. One is that they provide data on patients who might not participate in a clinical trial and may capture unusual adverse events that did not initially manifest in clinical trials. One such analysis was published by Wysowski et al, 32 comparing the reported vs the expected deaths in sildenafil users. They found that the number of deaths due to MI in sildenafil users was not greater than the number that would be expected for this age group.
Shakir et al 33 reported the results of a prescription event monitoring study performed in England. Questionnaires were filled out by 5601 sildenafil users with a mean age of 57. The mortality from ischemic heart disease and MI in this cohort was 30% lower than for the general population of English men in 1998 after adjusting for age. The authors concluded that there was no evidence for a higher incidence of death from MI or ischemic heart disease among men taking sildenafil than the general age-adjusted population. The same group recently updated their study with similar findings. 34 Post-marketing surveillance data regarding cardiovascular events have yet to be released for tadalafil and vardenafil.
Nitrates
Organic nitrates, including all of the preparations of nitroglycerin as well as isosorbide mononitrate and isosorbide dinitrate, are absolute contraindications to the use of PDE5 inhibitors. Organic nitrates are nitric oxide donors that result in an increased production of cGMP, the substance that ultimately causes relaxation of smooth muscle cells (vasodilation). PDE5 inhibitors prevent the degradation of cGMP. Hence, when a nitric oxide donor plus a PDE5 inhibitor are given at the same time, there is a synergistic degree of vasodilation that occurs in some patients (since PDE5 is located in the smooth muscle cells of the systemic vasculature) with hypotension. 35, 36 Nitrate-PDE5 inhibitor interaction has been described with all three of the PDE5 inhibitors currently on the market. If a patient develops angina when on a PDE5 inhibitor, when is it safe to give a nitrate? For the short-acting agents sildenafil and vardenafil (B4-h half-life), guidelines from the American College of Cardiology and American Heart Association recommend that 24 h (six half-lives) lapse prior to administration of nitrates. 19 While a preliminary study by Oliver et al 37 suggests that at least in healthy individuals the interaction between sildenafil and nitroglycerin may last less than 4 h, the study described results of mean changes in BP and not outliers. A study by Kloner et al 38 suggested that for the long half-life PDE5 inhibitor, tadalafil (17.5-h half-life), the interaction with nitroglycerin is still present at 24 h, but gone by 48 h after tadalafil.
The PDE5 inhibitors appear to have some interactions with alpha blockers in terms of added drops in BPs. At the time of this writing, the issues of these interactions being contraindications or precautions vary among the drugs as recently reviewed 39 and may be revisited by regulatory agencies.
Summary and guidelines
In summary, the PDE5 inhibitors are effective therapies for ED in men with CAD. They appear to be safe in most CAD patients. Most clinical studies did not, however, study these drugs in patients with unstable cardiac conditions. Guidelines issued by the American College of Cardiology/American Heart Association review the approach to using PDE5 inhibitors in patients with CAD. 19 The Princeton Consensus Guidelines suggest approaches in patients with various degrees of coronary risk. 40 Lowrisk patients can usually receive PDE5 inhibitors without additional cardiac workup. In high-risk, unstable cardiac patients, the workup for sexual dysfunction should be deferred until the cardiac problem has been corrected or stabilized. Patients with intermediate risk may need additional cardiac workup (such as an exercise stress test) and can then be reclassified to low risk or high risk before therapy for sexual therapy.
